Expertise in
19
conditions
Expertise in
19
conditions
Children's Hospital New Orleans
200 Henry Clay Ave, 
New Orleans, LA 

Overview

Lolie Yu is a Hematologist and an Oncologist in New Orleans, Louisiana. Dr. Yu has been practicing medicine for over 42 years is highly rated in 19 conditions, according to our data. Her top areas of expertise are Severe Combined Immunodeficiency (SCID), Hepatoblastoma, Langerhans Cell Histiocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 56 peer reviewed articles and participating in 81 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatrics in LA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Children's Hospital New Orleans
200 Henry Clay Ave, New Orleans, LA 70118

Additional Areas of Focus

Dr. Yu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


80 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
View 40 Less Clinical Trials
Similar Doctors
Expertise in
7
conditions
Hematology | Oncology
Expertise in
7
conditions
Hematology | Oncology

Tulane Healthy Mothers Clinic

1415 Tulane Ave Fl 5, 
New Orleans, LA 
 (3.0 miles away)
Languages Spoken:
English

Vivian Fonseca is a Hematologist and an Oncologist in New Orleans, Louisiana. Dr. Fonseca is highly rated in 7 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Low Blood Sugar, Maturity Onset Diabetes of the Young, Diabetic Neuropathy, and Hormone Replacement Therapy (HRT).

Expertise in
39
conditions
Expertise in
39
conditions

Ochsner Medical Center - New Orleans

1514 Jefferson Highway, 
New Orleans, LA 
 (1.6 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Marc Matrana is an Oncologist in New Orleans, Louisiana. Dr. Matrana is highly rated in 39 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Lung Cancer, Urothelial Cancer, Adult Soft Tissue Sarcoma, and Nephrectomy. Dr. Matrana is currently accepting new patients.

Expertise in
30
conditions
Hematology
Expertise in
30
conditions
Hematology

Office

150 S Liberty St, 
New Orleans, LA 
 (3.1 miles away)
Languages Spoken:
English
Offers Telehealth

Nakhle Saba is a Hematologist in New Orleans, Louisiana. Dr. Saba is highly rated in 30 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Lolie Yu

How do I make an appointment with Dr. Lolie Yu?

You can book an appointment with Dr. Lolie Yu by calling their office at 504-896-9740. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lolie Yu a top-rated expert for Severe Combined Immunodeficiency (SCID)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lolie Yu is classified as an Distinguished expert for Severe Combined Immunodeficiency (SCID), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lolie Yu specialize in?

While Dr. Lolie Yu is a Hematology, they have specific expertise in Severe Combined Immunodeficiency (SCID), Hepatoblastoma, and Langerhans Cell Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lolie Yu participate in research or clinical trials?

Yes. Dr. Lolie Yu has published 56 articles and abstracts on conditions like Severe Combined Immunodeficiency (SCID). You can view a list of Dr. Lolie Yu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lolie Yu accept my insurance?

Dr. Lolie Yu accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 504-896-9740 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yu's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile